Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007)

Dalbavancin is all antimicrobial lipoglycopeptide agent that has proven activity against Gram-positive pathogens and a once weekly closing advantage compared with other agents in the glycopeptide class. The most common pathogens isolated from skin and skin structure infections (SSSIs) include Staphylococcus aureus and beta-hemolytic streptococci (beta HS), and dalbavancin has demonstrated excellent activity against these species. This study used 18 medical center laboratories in 5 European countries to assess the activity of dalbavancin, vancomycin, and teicoplanin against S. aureus, coagulase-negative staphylococci (CoNS), and beta HS. The rank order of potency was dalbavancin (MIC(50), 0.06 mu g/mL) > teicoplanin (MIC(50), 0.5 mu g/mL) > vancomycin (MIC(50), 2 mu g/mL) and dalbavancin (MIC(50)), 0.06 mu g/mL) > teicoplanin and vancomycin (MIC(50), 2 mu g/mL) against S. aureus and CONS. respectively. Dalbavancin was the most active glycopeptide tested against beta HS with all strains inhibited by <= 0.12 mu g/mL. susceptibility to other antimicrobial classes was also evaluated with noticeable differences demonstrated between countries. Higher methicillin-resistant S. aureus (MRSA) rates were observed in Italy (44.2%) and the United Kingdom (36.8%) compared with other countries, but resistance to erythromycin (51.6-83.1%) and clindamycin (5.7-68.4%) among MRSA also varied significantly between countries. The excellent contemporary activity of dalbavancin against common Gram-positive pathogens collected in European Countries Suggests that dalbavancin Could have a role in the treatment of various types of SSSIs. (C) 2009 Elsevier Inc. All rights reserved.